AEterna Zentaris
1405 Boul Du Parc-technologique
Quebec
G1P 4P5
Canada
Tel: 418-652-8525
Fax: 418-652-0881
Website: http://www.aeternazentaris.com/
Email: aeterna@aeternazentaris.com
644 articles about AEterna Zentaris
-
Aeterna Zentaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Outlook
3/29/2022
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the year ended December 31, 2021.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Aeterna Zentaris Provides Update on Ongoing Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
3/21/2022
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today provided an update for its ongoing pivotal Phase 3 safety and efficacy study AEZS-130-P02 (the “DETECT-trial") evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency (CGHD).
-
Aeterna Zentaris Announces Expansion of Research Program with Julius-Maximilians-University Wuerzburg Aiming to Accelerate Development of Vaccine Programs
3/10/2022
Aeterna Zentaris Inc., a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, announced it has expanded the scope of its existing research program with the Julius-Maximilians-University Wuerzburg, on the development of COVID-19 and Chlamydia trachomatis vaccines.
-
Aeterna Zentaris Announces Notice of Allowance for U.S. Patent Covering AEZS-150 for the Potential Treatment of Chronic Hypoparathyroidism
3/2/2022
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that its licensor, The University of Sheffield, has received a notice of allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application No. 16/608,611.
-
Aeterna Zentaris to Present at the 2022 BIO CEO & Investor Conference
2/7/2022
Aeterna Zentaris Inc. announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at the BIO CEO & Investor Conference being held in New York, NY and virtually, February 14-17, 2022.
-
Aeterna Zentaris Provides Business Outlook and Outlines Pipeline Priorities
1/26/2022
Aeterna Zentaris Inc. today provided a corporate update and business outlook.
-
Aeterna Zentaris to Present at the Virtual Investor 2022 Top Picks Conference
1/20/2022
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at the Virtual Investor 2022 Top Picks Conference.
-
Aeterna Zentaris to Present at the H.C. Wainwright BioConnect Conference
1/5/2022
Aeterna Zentaris Inc. announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at the virtual H.C. Wainwright BioConnect Conference taking place January 10-13, 2022.
-
BioSpace Movers & Shakers, Dec. 31
12/31/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Aeterna Zentaris Appoints Giuliano La Fratta as Chief Financial Officer
12/23/2021
Aeterna Zentaris Inc., a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, announced the appointment of Giuliano La Fratta as Senior Vice President, Chief Financial Officer.
-
Aeterna Zentaris Reports Third Quarter 2021 Financial Results and Provides Pipeline Program Updates
11/4/2021
Aeterna Zentaris Inc., a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, reported its financial and operating results for the third quarter ended September 30, 2021.
-
Aeterna Zentaris to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
9/8/2021
Aeterna Zentaris Inc. announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.
-
Aeterna Zentaris Reports Second Quarter 2021 Financial Results and Provides Pipeline Program Updates
8/4/2021
Aeterna Zentaris Inc., a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, reported its financial and operating results for the second quarter ended June 30, 2021.
-
Aeterna Zentaris Engages Dr. Michael Levy to Support Development of Autoimmune and Inflammatory CNS Disorders Programs
6/7/2021
Aeterna Zentaris Inc. (NASDAQ: AEZS) today announced it has engaged neuroimmunologist, Michael Levy, MD, PhD, as a scientific consultant to support the development of the Company’s targeted, highly specific immunosuppressive therapeutic proteins (“AIM Biologicals”) for the potential treatment of neuromyelitis optica spectrum disorder (“NMOSD”).
-
Aeterna Zentaris Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
5/13/2021
– Safety and efficacy study for macimorelin initiated as agreed with U . S . FDA and the European Medicines Agency ("EMA") in the Company's Pediatric Investigation Plan ("PIP") – Patient enrollment on track to start this quarter – Planned completion of pivotal Phase 3 study expected in Q3 2022
-
Aeterna Zentaris to Present at the Q2 Virtual Investor Summit
5/10/2021
– Live video webcast with CEO, Dr. Klaus Paulini, on Monday, May 17, 2021 at 8:45 AM ET
-
Aeterna Zentaris Announces the Selection of a Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism
5/6/2021
– In collaboration, Aeterna and The University of Sheffield, UK have selected the development candidate AEZS-150, a parathyroid hormone (PTH) fusion polypeptide to start the formal preclinical development for potentially enabling the first in human clinical study. – AEZS-150 has the potential to become a new therapeutic treatment option of primary hypoparathyroidism.
-
Aeterna Zentaris Reports First Quarter 2021 Financial Results and Provides Pipeline Program Updates
5/5/2021
– Q1 2021 marked by solid operational execution with expansion and diversification of pipeline , intellectual property and portfolio of assets – P ivotal Phase 3 DET ECT (Study P02) safety and efficacy study evaluating macimorelin diagnostic for CGHD on track to commence in Q2 2021 – Strong balance sheet with cash expected to fund operations beyond 2023
-
Aeterna Zentaris Announces Results of 2021 Annual Meeting of Shareholders
5/5/2021
Aeterna Zentaris Inc., a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, announced the results from its Annual General Meeting held today, May 5, 2021.